Oncotype DX and MammaPrint are two genomic profile assays that have become essential resources to help understand the genomic risk of relapse and likely benefit from adjuvant chemotherapy for patients with early localized ER+ HER2-negative breast cancer. Here, ERBB2 is linked to breast carcinoma.